The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment.
about
Comparison of evidence on harms of medical interventions in randomized and nonrandomized studiesFebrile seizuresData mining in the US using the Vaccine Adverse Event Reporting System.Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.The complicated task of monitoring vaccine safety.Lessons learned and applied: what the 20th century vaccine experience can teach us about vaccines in the 21st centuryAcetaminophen and ibuprofen for prevention of adverse reactions associated with childhood immunization.Vaccines and febrile seizures.Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001-2010: content and utility analysis.Recombinant hemagglutinin influenza vaccine provides broader spectrum protection.Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of ageTracking vaccine lot lifecycles using reports to the vaccine adverse event reporting system (VAERS).Neurodevelopmental disorders following thimerosal-containing childhood immunizations: a follow-up analysis.An evaluation of the effects of thimerosal on neurodevelopmental disorders reported following DTP and Hib vaccines in comparison to DTPH vaccine in the United States.Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
P2860
Q24282604-A03AB5FC-9038-4C64-A7C7-4400C1572DB1Q27027264-648F55A4-D3A3-43EB-90A0-97E9097E7CEEQ31040237-608E1B43-A4E5-4049-B95A-4E7F109CD09EQ33999189-4EE2DEE3-E44F-4119-B112-D856DD703ED4Q34404953-2B019BB0-18AC-480E-A432-F19C3E9CF163Q36391852-91CBA100-1236-4FC5-BF4C-383E91D61E77Q36829153-0023B413-8F03-4A9D-AF39-2F2F78EF2E1BQ38132266-42D475C7-67AB-4157-8A2D-0D10F6582955Q39420922-F916792A-AF10-47F2-A51E-803164BBD1B8Q39675272-6B3CD79A-8F4C-467D-BDDB-BA6AED286793Q41907366-940D2AE5-E586-484E-BD59-03B1404CC19DQ43469723-D2BB1418-37C2-4D35-BFF5-D1F59FE060B5Q46375211-3BCCE11B-4CE2-43CF-8134-18F13D4C4FD1Q50109575-0A63B48D-5C73-48C8-A818-ED8E820B8AE9Q52558356-C57AE64D-A238-47AB-A2FF-CC5BF56501CB
P2860
The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
The safety of acellular pertus ...... e. A postmarketing assessment.
@en
type
label
The safety of acellular pertus ...... e. A postmarketing assessment.
@en
prefLabel
The safety of acellular pertus ...... e. A postmarketing assessment.
@en
P2093
P1433
P1476
The safety of acellular pertus ...... e. A postmarketing assessment.
@en
P2093
P304
P356
10.1001/ARCHPEDI.1996.02170300011001
P407
P577
1996-05-01T00:00:00Z